GERN - ジェロン (Geron Corporation) ジェロン

 GERNのチャート


 GERNの企業情報

symbol GERN
会社名 Geron Corp. (ジェロン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジェロン(Geron Corporation)はJanssen Biotech Inc. (Janssen)による血液骨髄性悪性腫瘍でファーストインクラスのテロメラーゼ阻害剤、imetelstatを開発する臨床段階のバイオ医薬品会社である。同社は、腫瘍学治療薬の開発に従事している。テロメラーゼのリボ核酸(RNA)鋳型に高親和性で結合し、それによってテロメラーゼ活性を直接阻害するオリゴヌクレオチドであるように、その核酸化学を用いて、イメテスタットを設計した。JanssenはIMbarkと呼ばれる骨髄線維症(MF)の第II相試験、IMergeと呼ばれる骨髄異形成症候群(MDS)の第II / III相試験などの2つの臨床試験でImetelstatの開発に従事する。Imetelstatは、テロメラーゼのRNA鋳型に相補的であり、それと高親和性で結合するように設計され、それによってテロメラーゼ活性を直接阻害するように設計された脂質結合13merオリゴヌクレオチドである。   ジェロンは米国のバイオ医薬品会社で、抗がん剤の開発に焦点に置く。現在製品化に向け、リンパ増殖性疾患、多発性骨髄腫、非小細胞肺がん、乳がん、急性骨髄性白血病のテロメラ―ゼ阻害剤であるイメテルスタットの治験を行う。また、骨髄線維症に対するテロメラ―ゼ阻害剤の予備研究を行う。   Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
本社所在地 149 Commonwealth Drive Suite 2070 Menlo Park CA 94025 USA
代表者氏名 Hoyoung Huh 湖寧
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-473-7700
設立年月日 33178
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 42人
url www.geron.com
nasdaq_url https://www.nasdaq.com/symbol/gern
adr_tso
EBITDA EBITDA(百万ドル) -29.64000
終値(lastsale) 1.835
時価総額(marketcap) 336946417.71
時価総額 時価総額(百万ドル) 306.64880
売上高 売上高(百万ドル) 0.88000
企業価値(EV) 企業価値(EV)(百万ドル) 145.72180
当期純利益 当期純利益(百万ドル) -28.44800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Geron Corporation revenues decreased 26% to $526K. Net loss increased 4% to $14.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 23% to $6.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.09 to -$0.08.

 GERNのテクニカル分析


 GERNのニュース

   Parametric Portfolio Associates LLC Has $237,000 Holdings in Geron Co. (NASDAQ:GERN)  2021/12/24 09:08:41 Dakota Financial News
Parametric Portfolio Associates LLC increased its stake in Geron Co. (NASDAQ:GERN) by 76.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 167,920 shares of the biopharmaceutical companys stock after buying an additional 72,571 shares during the quarter. Parametric Portfolio Associates []
   Geron Corporation (GERN) Falls -1.49%, Causing Bears To Lose  2021/12/22 13:30:00 Marketing Sentinel
Geron Corporation (NASDAQ:GERN) has a beta value of 1.06 and has seen 1.85 million shares traded in the last trading session. The company, currently valued at $415.51M, closed the last trade at $1.32 per share which meant it lost -$0.02 on the day or -1.49% during that session. The GERN stock price is -78.79% off Geron Corporation (GERN) Falls -1.49%, Causing Bears To Lose Read More »
   Geron Corporation 2021 Q2 - Results - Earnings Call Presentation  2021/12/15 01:33:25 Seeking Alpha
   Geron Reports Presentations at American Society of Hematology Annual Meeting  2021/12/14 21:30:00 Kwhen Finance
   Parametric Portfolio Associates LLC Has $237,000 Holdings in Geron Co. (NASDAQ:GERN)  2021/12/24 09:08:41 Dakota Financial News
Parametric Portfolio Associates LLC increased its stake in Geron Co. (NASDAQ:GERN) by 76.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 167,920 shares of the biopharmaceutical companys stock after buying an additional 72,571 shares during the quarter. Parametric Portfolio Associates []
   Geron Corporation (GERN) Falls -1.49%, Causing Bears To Lose  2021/12/22 13:30:00 Marketing Sentinel
Geron Corporation (NASDAQ:GERN) has a beta value of 1.06 and has seen 1.85 million shares traded in the last trading session. The company, currently valued at $415.51M, closed the last trade at $1.32 per share which meant it lost -$0.02 on the day or -1.49% during that session. The GERN stock price is -78.79% off Geron Corporation (GERN) Falls -1.49%, Causing Bears To Lose Read More »
   Geron Corporation 2021 Q2 - Results - Earnings Call Presentation  2021/12/15 01:33:25 Seeking Alpha
   Geron Reports Presentations at American Society of Hematology Annual Meeting  2021/12/14 21:30:00 Kwhen Finance
   Geron Announces September Investor Conference Presentation Webcasts  2021/09/01 20:30:00 Business Wire
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Gerons Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: H.C. Wainwright 23rd Annual Global Virtual Investment Conference on Monday, September 13, 2021 at 7:00 a.m. ET. R.W. Baird 2021 Virtual Global Healthcare Conference on Tuesday, September 14, 2021 at 2:00 p.m. ET. 2021 Cantor Virtual Global Healthcare Conference on Thursday,
   Geron: Potential For Mind-Bending Returns With Current Pipeline  2021/08/19 13:00:00 Seeking Alpha
   Geron (GERN) Q2 2021 Earnings Call Transcript  2021/08/17 09:00:39 The Motley Fool
GERN earnings call for the period ending June 30, 2021.
   Geron EPS in-line, beats on revenue  2021/08/16 20:07:05 Seeking Alpha
   How Have the Numbers Shaped Up for Geron (NASDAQ:GERN)  2021/08/16 17:00:00 Stock Market Daily
Earnings results for Geron , Analyst Opinion on Geron , Earnings and Valuation of (NASDAQ:GERN), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post How Have the Numbers Shaped Up for Geron (NASDAQ:GERN) appeared first on .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェロン GERN Geron Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)